Eli Lilly pens pact with Banner Alzheimer's Institute for ‘virtual approach’ for its late-stage donanemab test

The unexpected FDA approval of Aduhlem appears to have spurred Lilly back into action, and its gunning full speed ahead with a phase 3 trial, known as TRAILBLAZER-ALZ 3, to fully assess whether donanemab can slow the clinical progression of Alzheimer's disease in trial participants.

To help with the trial, Lilly is teaming up with the Banner Alzheimer's Institute, a 15-year-old organization that is seeking to help find treatments and prevention for the memory-wasting disease, to help seek subjects that either have, or do not have, the e4 type of the apolipoprotein E (APOE4) gene, which it will find via its Alzheimer's Prevention Registry's GeneMatch program. This gene is believed to be a biomarker for an increased risk of the disease,